Eisai, Arena Expand Marketing Agreement For Belviq Diet Drug
This article was originally published in PharmAsia News
Executive Summary
Eisai and Arena Pharmaceuticals plan to expand a marketing agreement for the U.S. drug maker's diet drug Belviq (lorcaserin) to allow the Japan company to market it in all but five nations.